Shares of ValiRx plc (LON:VAL – Get Free Report) hit a new 52-week low during trading on Tuesday . The stock traded as low as GBX 1.21 ($0.02) and last traded at GBX 1.21 ($0.02), with a volume of 227160 shares traded. The stock had previously closed at GBX 1.25 ($0.02).
ValiRx Price Performance
The company has a quick ratio of 1.27, a current ratio of 6.65 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of £1.65 million, a price-to-earnings ratio of -60.65 and a beta of 0.59. The stock has a 50 day moving average of GBX 1.91 and a 200 day moving average of GBX 2.60.
About ValiRx
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Featured Articles
- Five stocks we like better than ValiRx
- There Are Different Types of Stock To Invest In
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- What is a support level?
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- How to Invest in the FAANG Stocks
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
